Contemporary Management and Outcomes of Veterans Hospitalized With Alcohol Withdrawal: A Multicenter Retrospective Cohort Study

Author:

Ronan Matthew V.,Gordon Kirsha S.,Skanderson Melissa,Krug Michael,Godwin Patrick,Heppe Daniel,Hoegh Matthew,Boggan Joel C.,Gutierrez Jeydith,Kaboli Peter,Pescetto Micah,Guidry Michelle,Caldwell Peter,Mitchell Christine,Ehlers Erik,Allaudeen Nazima,Cyr Jessica,Smeraglio Andrea,Yarbrough Peter,Rose Richard,Jagannath Anand,Vargas Jaclyn,Cornia Paul B.,Shah Meghna,Tuck Matthew,Arundel Cherinne,Laudate James,Elzweig Joel,Rodwin Benjamin,Akwe Joyce,Trubitt Meredith,Gunderson Craig G.

Abstract

Objectives Few studies describe contemporary alcohol withdrawal management in hospitalized settings or review current practices considering the guidelines by the American Society of Addiction Medicine (ASAM). Methods We conducted a retrospective cohort study of patients hospitalized with alcohol withdrawal on medical or surgical wards in 19 Veteran Health Administration (VHA) hospitals between October 1, 2018, and September 30, 2019. Demographic and comorbidity data were obtained from the Veteran Health Administration Corporate Data Warehouse. Inpatient management and hospital outcomes were obtained by chart review. Factors associated with treatment duration and complicated withdrawal were examined. Results Of the 594 patients included in this study, 51% were managed with symptom-triggered therapy alone, 26% with fixed dose plus symptom-triggered therapy, 10% with front loading regimens plus symptom-triggered therapy, and 3% with fixed dose alone. The most common medication given was lorazepam (87%) followed by chlordiazepoxide (33%), diazepam (14%), and phenobarbital (6%). Symptom-triggered therapy alone (relative risk [RR], 0.68; 95% confidence interval [CI], 0.57–0.80) and front loading with symptom-triggered therapy (RR, 0.75; 95% CI, 0.62–0.92) were associated with reduced treatment duration. Lorazepam (RR, 1.20; 95% CI, 1.02–1.41) and phenobarbital (RR, 1.28; 95% CI, 1.06–1.54) were associated with increased treatment duration. Lorazepam (adjusted odds ratio, 4.30; 95% CI, 1.05–17.63) and phenobarbital (adjusted odds ratio, 6.51; 95% CI, 2.08–20.40) were also associated with complicated withdrawal. Conclusions Overall, our results support guidelines by the ASAM to manage patients with long-acting benzodiazepines using symptom-triggered therapy. Health care systems that are using shorter acting benzodiazepines and fixed-dose regimens should consider updating alcohol withdrawal management pathways to follow ASAM recommendations.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3